Post-earnings recap
Reported
Tue, Sep 1, 2026
EPS actual
$0.00
EPS est.
$0.09
EPS surprise
-100.00%
1-day move
+10.66%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing EPS expectations, MiniMed's stock rose by 10.66%, likely driven by strong organic revenue growth and positive management outlook. The successful launch of the MiniMed Flex insulin pump and growth in new prescribers contributed to this positive sentiment. Investors may be encouraged by the raised revenue guidance and ongoing innovation efforts.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.00 | N/A | -100.00% |
| U.S. Revenue Growth | 13% | N/A | N/A |
| International Revenue Growth | 16.9% | N/A | N/A |
| New Pumps Sold Growth | 20% | N/A | N/A |
Management expressed confidence in the company's growth trajectory, highlighting strong performance in both U.S. and international markets. They also emphasized ongoing innovation efforts.
Management raised FY27 organic revenue growth guidance to 10.5%.
The company is advancing its innovation pipeline, including the upcoming MiniMed Fit patch pump.